Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1992-4-1
|
pubmed:abstractText |
To determine the immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in specific populations at risk, we administered vaccine to children with sickle cell anemia (n = 19; mean age, 18.3 months, malignancies (n = 18; mean age, 43.1 months), or a recent history of systemic H. influenzae type b infection (n = 17; mean age, 11.9 months). After one dose of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine the geometric mean titers for polyribosylribitol phosphate antibody were 4.8 micrograms/ml (14/19 greater than 1 microgram/ml), 1.4 micrograms/ml (9/18 greater than 1 microgram/ml), and 5.6 micrograms/ml (15/17 greater than 1 microgram/ml) in these three groups, respectively. Children with sickle cell anemia or a recent history of systemic H. influenzae type b infection had polyribosylribitol phosphate antibody levels comparable to those of normal children of similar age after one or two doses of polyribosylribitol phosphate-tetanus toxoid conjugate vaccine. We conclude that this vaccine is immunogenic in children with underlying conditions associated with an increased risk of H. influenzae type b infection.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Bacterial Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Haemophilus Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Haemophilus influenza type b...,
http://linkedlifedata.com/resource/pubmed/chemical/Pentosephosphates,
http://linkedlifedata.com/resource/pubmed/chemical/Polysaccharides, Bacterial,
http://linkedlifedata.com/resource/pubmed/chemical/Tetanus Toxoid,
http://linkedlifedata.com/resource/pubmed/chemical/polyribose phosphate
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0022-3476
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
120
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
367-70
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1538281-Anemia, Sickle Cell,
pubmed-meshheading:1538281-Antibodies, Bacterial,
pubmed-meshheading:1538281-Bacterial Vaccines,
pubmed-meshheading:1538281-Child, Preschool,
pubmed-meshheading:1538281-Haemophilus Infections,
pubmed-meshheading:1538281-Haemophilus Vaccines,
pubmed-meshheading:1538281-Haemophilus influenzae,
pubmed-meshheading:1538281-Humans,
pubmed-meshheading:1538281-Infant,
pubmed-meshheading:1538281-Neoplasms,
pubmed-meshheading:1538281-Pentosephosphates,
pubmed-meshheading:1538281-Polysaccharides, Bacterial,
pubmed-meshheading:1538281-Tetanus Toxoid
|
pubmed:year |
1992
|
pubmed:articleTitle |
Immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children with sickle hemoglobinopathy or malignancies, and after systemic Haemophilus influenzae type b infection.
|
pubmed:affiliation |
Department of Pediatrics, Baylor College of Medicine, Houston, TX.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|